Corbus Pharmaceuticals Reports Promising Data for CRB-701 and CRB-913, Extends Cash Runway to 2028 — Corbus Pharmaceuticals Holdings, Inc.

Event summary

Corbus Pharmaceuticals reported encouraging Phase 1/2 data for CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer, with objective response rates of 47.6% and 37.5% respectively.
CRB-913 demonstrated a 2.9% weight loss at 14 days in a dedicated obesity cohort, with favorable GI safety and no neuropsychiatric side effects.
Completed a $75 million public offering in Q4 2025, extending cash runway into 2028.
Deprioritized CRB-601 program and will not enroll additional patients.

The big picture

Corbus Pharmaceuticals is positioning itself at the intersection of oncology and obesity treatment, two high-growth areas in biotech. The promising data for CRB-701 and CRB-913, combined with a robust cash position, sets the stage for potential transformative milestones in 2026. The company's strategic focus on these two programs, coupled with the deprioritization of CRB-601, underscores a shift towards high-impact therapeutic areas with significant market potential.

What we're watching

Regulatory Pathway: Whether the FDA discussions in Q1 2026 will clarify the registrational study protocols for CRB-701 in HNSCC and cervical cancer.
Clinical Efficacy: The durability data and patient stratification insights from the mid-2026 CRB-701 monotherapy data readout.
Market Potential: The pace at which CRB-913 can establish itself as a novel long-term weight management solution following the completion of the CANYON-1 Phase 1b study in summer 2026.